Intellect Neurosciences, Inc.
7 West 18th Street
9th Floor
New York,
NY 10011
United States - Map
Phone: 212-448-9300
Fax: 212-448-9600
Web Site: http://www.intellectns.com
| Intellect Neurosciences, Inc., a biopharmaceutical company, engages in the research and development of proprietary drug candidates for the treatment of Alzheimers disease and other diseases associated with oxidative stress. The companys drugs are based on its immunotherapy platform technologies, ANTISENILIN and RECALL-VAX. Its product candidates include IN-N01, a monoclonal antibody to prevent the accumulation and toxicity of the beta amyloid toxin; and OXIGON, a small molecule that targets the underlying pathology of the disease through a dual mode of action having anti-oxidant and anti-fibrilogenic activity. The company also involves in identifying drug candidates based on its RECALL-VAX technology, which uses chimeric peptides as vaccines to immunize patients with Alzheimers disease or individuals, who are susceptible to developing the disease because of age or other risk factors. It has a license agreement with AHP MANUFACTURING BV for the research, development, manufacture, and commercialization of therapeutic products for the treatment of Alzheimers disease. The company was founded in 2005 and is headquartered in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Daniel G. Chain Ph.D., 52
Chairman and Chief Exec. Officer |
N/A
| N/A | Mr. Elliot M. Maza J.D., C.P.A., 50
Pres, Chief Financial Officer |
N/A
| N/A | Dr. Rachel Eren Ph.D.,
VP of Research |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.03% Nasdaq 0.00%
Profile
